A71 Stock Overview
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Ascendis Pharma A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$127.00 |
52 Week High | US$147.00 |
52 Week Low | US$81.50 |
Beta | 0.51 |
1 Month Change | -7.30% |
3 Month Change | 2.42% |
1 Year Change | n/a |
3 Year Change | 5.83% |
5 Year Change | 19.81% |
Change since IPO | 659.43% |
Recent News & Updates
Recent updates
Shareholder Returns
A71 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -3.1% | 0.8% | 1.2% |
1Y | n/a | -24.4% | 2.0% |
Return vs Industry: Insufficient data to determine how A71 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how A71 performed against the German Market.
Price Volatility
A71 volatility | |
---|---|
A71 Average Weekly Movement | 5.1% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: A71 has not had significant price volatility in the past 3 months.
Volatility Over Time: A71's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 879 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
A71 fundamental statistics | |
---|---|
Market cap | €7.24b |
Earnings (TTM) | -€481.45m |
Revenue (TTM) | €266.72m |
28.0x
P/S Ratio-15.5x
P/E RatioIs A71 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A71 income statement (TTM) | |
---|---|
Revenue | €266.72m |
Cost of Revenue | €44.40m |
Gross Profit | €222.32m |
Other Expenses | €703.77m |
Earnings | -€481.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | -8.43 |
Gross Margin | 83.36% |
Net Profit Margin | -180.51% |
Debt/Equity Ratio | -374.4% |
How did A71 perform over the long term?
See historical performance and comparison